ID   SMG1_HUMAN              Reviewed;        3661 AA.
AC   Q96Q15; O43305; Q13284; Q8NFX2; Q96QV0; Q96RW3;
DT   04-APR-2006, integrated into UniProtKB/Swiss-Prot.
DT   08-FEB-2011, sequence version 3.
DT   10-MAY-2017, entry version 143.
DE   RecName: Full=Serine/threonine-protein kinase SMG1;
DE            Short=SMG-1;
DE            Short=hSMG-1;
DE            EC=2.7.11.1;
DE   AltName: Full=61E3.4;
DE   AltName: Full=Lambda/iota protein kinase C-interacting protein;
DE            Short=Lambda-interacting protein;
GN   Name=SMG1; Synonyms=ATX, KIAA0421, LIP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RX   PubMed=9566925; DOI=10.1128/MCB.18.5.3069;
RA   Sanchez P., De Carcer G., Sandoval I.V., Moscat J., Diaz-Meco M.T.;
RT   "Localization of atypical protein kinase C isoforms into lysosome-
RT   targeted endosomes through interaction with p62.";
RL   Mol. Cell. Biol. 18:3069-3080(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, PHOSPHORYLATION OF
RP   RENT1, ALTERNATIVE SPLICING, ENZYME REGULATION, PHOSPHORYLATION,
RP   INTERACTION WITH RENT1; UPF2 AND UPF3, AND MUTAGENESIS OF ASP-2335.
RX   PubMed=11544179; DOI=10.1101/gad.913001;
RA   Yamashita A., Ohnishi T., Kashima I., Taya Y., Ohno S.;
RT   "Human SMG-1, a novel phosphatidylinositol 3-kinase-related protein
RT   kinase, associates with components of the mRNA surveillance complex
RT   and is involved in the regulation of nonsense-mediated mRNA decay.";
RL   Genes Dev. 15:2215-2228(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, PHOSPHORYLATION OF
RP   RENT1, COFACTOR, ENZYME REGULATION, AND MUTAGENESIS OF ASP-2335.
RX   PubMed=11331269; DOI=10.1074/jbc.C100144200;
RA   Denning G., Jamieson L., Maquat L.E., Thompson E.A., Fields A.P.;
RT   "Cloning of a novel phosphatidylinositol kinase-related kinase:
RT   characterization of the human SMG-1 RNA surveillance protein.";
RL   J. Biol. Chem. 276:22709-22714(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, PHOSPHORYLATION OF
RP   TP53, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, ENZYME REGULATION,
RP   MUTAGENESIS OF ASP-2335, AND VARIANTS CYS-144 AND LYS-612.
RX   PubMed=15175154; DOI=10.1016/j.molcel.2004.05.005;
RA   Brumbaugh K.M., Otterness D.M., Geisen C., Oliveira V., Brognard J.,
RA   Li X., Lejeune F., Tibbetts R.S., Maquat L.E., Abraham R.T.;
RT   "The mRNA surveillance protein hSMG-1 functions in genotoxic stress
RT   response pathways in mammalian cells.";
RL   Mol. Cell 14:585-598(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1674-3661.
RC   TISSUE=Brain;
RX   PubMed=9455477; DOI=10.1093/dnares/4.5.307;
RA   Ishikawa K., Nagase T., Nakajima D., Seki N., Ohira M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VIII.
RT   78 new cDNA clones from brain which code for large proteins in
RT   vitro.";
RL   DNA Res. 4:307-313(1997).
RN   [7]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2878-3661, TISSUE SPECIFICITY, AND
RP   INTERACTION WITH PRKCI.
RX   PubMed=8524286; DOI=10.1128/MCB.16.1.105;
RA   Diaz-Meco M.T., Municio M.M., Sanchez P., Lozano J., Moscat J.;
RT   "Lambda-interacting protein, a novel protein that specifically
RT   interacts with the zinc finger domain of the atypical protein kinase C
RT   isotype lambda/iota and stimulates its kinase activity in vitro and in
RT   vivo.";
RL   Mol. Cell. Biol. 16:105-114(1996).
RN   [9]
RP   DUPLICATION.
RX   PubMed=11948212; DOI=10.1093/jhered/92.6.462;
RA   Eichler E.E., Johnson M.E., Alkan C., Tuzun E., Sahinalp C.,
RA   Misceo D., Archidiacono N., Rocchi M.;
RT   "Divergent origins and concerted expansion of two segmental
RT   duplications on chromosome 16.";
RL   J. Hered. 92:462-468(2001).
RN   [10]
RP   INTERACTION WITH SMG5.
RX   PubMed=14636577; DOI=10.1016/S1097-2765(03)00443-X;
RA   Ohnishi T., Yamashita A., Kashima I., Schell T., Anders K.R.,
RA   Grimson A., Hachiya T., Hentze M.W., Anderson P., Ohno S.;
RT   "Phosphorylation of hUPF1 induces formation of mRNA surveillance
RT   complexes containing hSMG-5 and hSMG-7.";
RL   Mol. Cell 12:1187-1200(2003).
RN   [11]
RP   INTERACTION WITH RENT1; UPF2; EST1A AND UPF3B.
RX   PubMed=12554878; DOI=10.1261/rna.2137903;
RA   Chiu S.-Y., Serin G., Ohara O., Maquat L.E.;
RT   "Characterization of human Smg5/7a: a protein with similarities to
RT   Caenorhabditis elegans SMG5 and SMG7 that functions in the
RT   dephosphorylation of Upf1.";
RL   RNA 9:77-87(2003).
RN   [12]
RP   FUNCTION, INTERACTION WITH UPF2, AND IDENTIFICATION IN THE SURF
RP   COMPLEX.
RX   PubMed=16452507; DOI=10.1101/gad.1389006;
RA   Kashima I., Yamashita A., Izumi N., Kataoka N., Morishita R.,
RA   Hoshino S., Ohno M., Dreyfuss G., Ohno S.;
RT   "Binding of a novel SMG-1-Upf1-eRF1-eRF3 complex (SURF) to the exon
RT   junction complex triggers Upf1 phosphorylation and nonsense-mediated
RT   mRNA decay.";
RL   Genes Dev. 20:355-367(2006).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-3550 AND SER-3556, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3570, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [17]
RP   CATALYTIC ACTIVITY, AND IDENTIFICATION IN THE SMG1C COMPLEX.
RX   PubMed=19417104; DOI=10.1101/gad.1767209;
RA   Yamashita A., Izumi N., Kashima I., Ohnishi T., Saari B.,
RA   Katsuhata Y., Muramatsu R., Morita T., Iwamatsu A., Hachiya T.,
RA   Kurata R., Hirano H., Anderson P., Ohno S.;
RT   "SMG-8 and SMG-9, two novel subunits of the SMG-1 complex, regulate
RT   remodeling of the mRNA surveillance complex during nonsense-mediated
RT   mRNA decay.";
RL   Genes Dev. 23:1091-1105(2009).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-173, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [20]
RP   INTERACTION WITH TELO2 AND TTI1.
RX   PubMed=20427287; DOI=10.1074/jbc.M110.121699;
RA   Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K.,
RA   Iemura S., Natsume T., Mizushima N.;
RT   "Tti1 and Tel2 are critical factors in mammalian target of rapamycin
RT   complex assembly.";
RL   J. Biol. Chem. 285:20109-20116(2010).
RN   [21]
RP   INTERACTION WITH TTI1.
RX   PubMed=20810650; DOI=10.1101/gad.1934210;
RA   Hurov K.E., Cotta-Ramusino C., Elledge S.J.;
RT   "A genetic screen identifies the Triple T complex required for DNA
RT   damage signaling and ATM and ATR stability.";
RL   Genes Dev. 24:1939-1950(2010).
RN   [22]
RP   INTERACTION WITH RUVBL1 AND RUVBL2.
RX   PubMed=20371770; DOI=10.1126/scisignal.2000468;
RA   Izumi N., Yamashita A., Iwamatsu A., Kurata R., Nakamura H., Saari B.,
RA   Hirano H., Anderson P., Ohno S.;
RT   "AAA+ proteins RUVBL1 and RUVBL2 coordinate PIKK activity and function
RT   in nonsense-mediated mRNA decay.";
RL   Sci. Signal. 3:RA27-RA27(2010).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-3573, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   INTERACTION WITH SMG8 AND SMG9, AND ELECTRON MICROSCOPY OF THE SMG1C
RP   COMPLEX.
RX   PubMed=21245168; DOI=10.1101/gad.606911;
RA   Arias-Palomo E., Yamashita A., Fernandez I.S., Nunez-Ramirez R.,
RA   Bamba Y., Izumi N., Ohno S., Llorca O.;
RT   "The nonsense-mediated mRNA decay SMG-1 kinase is regulated by large-
RT   scale conformational changes controlled by SMG-8.";
RL   Genes Dev. 25:153-164(2011).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-3550; SER-3556; SER-3570
RP   AND THR-3573, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-3573, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [29]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-35; CYS-126; CYS-144; TYR-151;
RP   ASN-160; VAL-167; GLY-320; SER-465; ARG-546; SER-588; LYS-612;
RP   CYS-753; CYS-809; CYS-812; ILE-829; ASP-832; GLY-952; SER-969;
RP   LEU-1016; GLN-1029; SER-1072; HIS-1103; ARG-1275; PRO-1292; VAL-1332;
RP   PRO-1358; THR-1418; CYS-2171; SER-2258; LYS-2345; GLU-2730; SER-2889;
RP   ALA-2899; THR-3239 AND GLN-3583.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine protein kinase involved in both mRNA
CC       surveillance and genotoxic stress response pathways. Recognizes
CC       the substrate consensus sequence [ST]-Q. Plays a central role in
CC       nonsense-mediated decay (NMD) of mRNAs containing premature stop
CC       codons by phosphorylating UPF1/RENT1. Recruited by release factors
CC       to stalled ribosomes together with SMG8 and SMG9 (forming the
CC       SMG1C protein kinase complex), and UPF1 to form the transient SURF
CC       (SMG1-UPF1-eRF1-eRF3) complex. In EJC-dependent NMD, the SURF
CC       complex associates with the exon junction complex (EJC) through
CC       UPF2 and allows the formation of an UPF1-UPF2-UPF3 surveillance
CC       complex which is believed to activate NMD. Also acts as a
CC       genotoxic stress-activated protein kinase that displays some
CC       functional overlap with ATM. Can phosphorylate p53/TP53 and is
CC       required for optimal p53/TP53 activation after cellular exposure
CC       to genotoxic stress. Its depletion leads to spontaneous DNA damage
CC       and increased sensitivity to ionizing radiation (IR). May activate
CC       PRKCI but not PRKCZ. {ECO:0000269|PubMed:11331269,
CC       ECO:0000269|PubMed:11544179, ECO:0000269|PubMed:15175154,
CC       ECO:0000269|PubMed:16452507}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:19417104}.
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:11331269};
CC   -!- ENZYME REGULATION: Inhibited by caffeine, LY294002 and wortmannin.
CC       {ECO:0000269|PubMed:11331269, ECO:0000269|PubMed:11544179,
CC       ECO:0000269|PubMed:15175154}.
CC   -!- SUBUNIT: Component of the SMG1C complex composed of SMG1, SMG8 and
CC       SMG9; the recruitment of SMG8 to SMG1 N-terminus induces a large
CC       conformational change in the SMG1 C-terminal head domain
CC       containing the catalytic domain. Component of the transient SURF
CC       (SMG1-UPF1-eRF1-eRF3) complex. Interacts with PRKCI. Interacts
CC       with TELO2 and TTI1. Interacts with RUVBL1 and RUVBL2. Interacts
CC       with UPF2. {ECO:0000269|PubMed:11544179,
CC       ECO:0000269|PubMed:12554878, ECO:0000269|PubMed:14636577,
CC       ECO:0000269|PubMed:16452507, ECO:0000269|PubMed:19417104,
CC       ECO:0000269|PubMed:20371770, ECO:0000269|PubMed:20427287,
CC       ECO:0000269|PubMed:20810650, ECO:0000269|PubMed:21245168,
CC       ECO:0000269|PubMed:8524286}.
CC   -!- INTERACTION:
CC       P11940:PABPC1; NbExp=2; IntAct=EBI-1049832, EBI-81531;
CC       Q9HAU5:UPF2; NbExp=7; IntAct=EBI-1049832, EBI-372073;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15175154}.
CC       Cytoplasm {ECO:0000269|PubMed:15175154}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q96Q15-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96Q15-2; Sequence=VSP_017748;
CC       Name=3;
CC         IsoId=Q96Q15-3; Sequence=VSP_017747;
CC       Name=4; Synonyms=BLIP;
CC         IsoId=Q96Q15-4; Sequence=VSP_017746;
CC   -!- TISSUE SPECIFICITY: Widely expressed, with highest level in heart
CC       and skeletal muscle. Expressed in placenta, brain, lung and
CC       spleen, but not in liver. {ECO:0000269|PubMed:15175154,
CC       ECO:0000269|PubMed:8524286}.
CC   -!- PTM: Autophosphorylated. {ECO:0000305|PubMed:11331269,
CC       ECO:0000305|PubMed:11544179, ECO:0000305|PubMed:15175154}.
CC   -!- MISCELLANEOUS: This gene is located in a region of chromosome 16
CC       that contains 2 segmental duplications. Other genes that are
CC       highly related to this exist, but they probably represent
CC       pseudogenes.
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA86535.2; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF186377; AAK58892.1; -; mRNA.
DR   EMBL; AB061371; BAB70696.1; -; mRNA.
DR   EMBL; AY014957; AAK00511.1; -; mRNA.
DR   EMBL; AF395444; AAM73708.1; -; mRNA.
DR   EMBL; AC092287; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB007881; BAA24851.2; -; mRNA.
DR   EMBL; U32581; AAA86535.2; ALT_INIT; mRNA.
DR   CCDS; CCDS45430.1; -. [Q96Q15-1]
DR   PIR; JC6084; JC6084.
DR   RefSeq; NP_055907.3; NM_015092.4. [Q96Q15-1]
DR   UniGene; Hs.460179; -.
DR   ProteinModelPortal; Q96Q15; -.
DR   BioGrid; 116687; 31.
DR   IntAct; Q96Q15; 31.
DR   MINT; MINT-1513197; -.
DR   STRING; 9606.ENSP00000402515; -.
DR   BindingDB; Q96Q15; -.
DR   ChEMBL; CHEMBL1795195; -.
DR   GuidetoPHARMACOLOGY; 2201; -.
DR   iPTMnet; Q96Q15; -.
DR   PhosphoSitePlus; Q96Q15; -.
DR   BioMuta; SMG1; -.
DR   DMDM; 322510104; -.
DR   EPD; Q96Q15; -.
DR   MaxQB; Q96Q15; -.
DR   PaxDb; Q96Q15; -.
DR   PeptideAtlas; Q96Q15; -.
DR   PRIDE; Q96Q15; -.
DR   Ensembl; ENST00000446231; ENSP00000402515; ENSG00000157106. [Q96Q15-1]
DR   GeneID; 23049; -.
DR   KEGG; hsa:23049; -.
DR   UCSC; uc002dfm.4; human. [Q96Q15-1]
DR   CTD; 23049; -.
DR   DisGeNET; 23049; -.
DR   GeneCards; SMG1; -.
DR   H-InvDB; HIX0012849; -.
DR   H-InvDB; HIX0038625; -.
DR   H-InvDB; HIX0202313; -.
DR   HGNC; HGNC:30045; SMG1.
DR   HPA; HPA006870; -.
DR   HPA; HPA031623; -.
DR   HPA; HPA073972; -.
DR   MIM; 607032; gene.
DR   neXtProt; NX_Q96Q15; -.
DR   OpenTargets; ENSG00000157106; -.
DR   PharmGKB; PA164725852; -.
DR   eggNOG; KOG0891; Eukaryota.
DR   eggNOG; COG5032; LUCA.
DR   GeneTree; ENSGT00870000136468; -.
DR   HOGENOM; HOG000168703; -.
DR   HOVERGEN; HBG093965; -.
DR   InParanoid; Q96Q15; -.
DR   KO; K08873; -.
DR   OMA; NLMIVHG; -.
DR   OrthoDB; EOG091G0072; -.
DR   PhylomeDB; Q96Q15; -.
DR   TreeFam; TF352560; -.
DR   Reactome; R-HSA-975957; Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC).
DR   SIGNOR; Q96Q15; -.
DR   ChiTaRS; SMG1; human.
DR   GeneWiki; SMG1_(gene); -.
DR   GenomeRNAi; 23049; -.
DR   PRO; PR:Q96Q15; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000157106; -.
DR   ExpressionAtlas; Q96Q15; baseline and differential.
DR   Genevisible; Q96Q15; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; TAS:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0042162; F:telomeric DNA binding; IDA:BHF-UCL.
DR   GO; GO:0006281; P:DNA repair; IEA:UniProtKB-KW.
DR   GO; GO:0006406; P:mRNA export from nucleus; TAS:UniProtKB.
DR   GO; GO:0000184; P:nuclear-transcribed mRNA catabolic process, nonsense-mediated decay; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0046854; P:phosphatidylinositol phosphorylation; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0032204; P:regulation of telomere maintenance; IMP:BHF-UCL.
DR   GO; GO:0006950; P:response to stress; IDA:UniProtKB.
DR   Gene3D; 1.10.1070.11; -; 1.
DR   Gene3D; 1.25.10.10; -; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR003152; FATC_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000403; PI3/4_kinase_cat_dom.
DR   InterPro; IPR018936; PI3/4_kinase_CS.
DR   InterPro; IPR014009; PIK_FAT.
DR   InterPro; IPR031559; SMG1.
DR   Pfam; PF02260; FATC; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   Pfam; PF15785; SMG1; 1.
DR   SMART; SM01343; FATC; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SUPFAM; SSF48371; SSF48371; 5.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS51189; FAT; 1.
DR   PROSITE; PS51190; FATC; 1.
DR   PROSITE; PS00916; PI3_4_KINASE_2; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; ATP-binding; Complete proteome;
KW   Cytoplasm; DNA damage; DNA repair; Kinase; Manganese; Metal-binding;
KW   Nonsense-mediated mRNA decay; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1   3661       Serine/threonine-protein kinase SMG1.
FT                                /FTId=PRO_0000229791.
FT   DOMAIN     1131   1866       FAT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00534}.
FT   REPEAT     1817   1852       HEAT.
FT   DOMAIN     2150   2478       PI3K/PI4K. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00269}.
FT   DOMAIN     3629   3661       FATC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00534, ECO:0000255|PROSITE-
FT                                ProRule:PRU00535}.
FT   REGION        1   1977       Interaction with SMG8 and SMG9.
FT                                {ECO:0000269|PubMed:21245168}.
FT   MOD_RES     173    173       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    3550   3550       Phosphothreonine.
FT                                {ECO:0000244|PubMed:17525332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3556   3556       Phosphoserine.
FT                                {ECO:0000244|PubMed:17525332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3570   3570       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3573   3573       Phosphothreonine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    3577   3577       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q8BKX6}.
FT   VAR_SEQ       1   1269       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:9566925}.
FT                                /FTId=VSP_017746.
FT   VAR_SEQ       1    630       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:11331269}.
FT                                /FTId=VSP_017747.
FT   VAR_SEQ       1    140       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15175154}.
FT                                /FTId=VSP_017748.
FT   VARIANT      35     35       A -> T (in dbSNP:rs12051350).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041623.
FT   VARIANT     126    126       R -> C (in dbSNP:rs752796432).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041624.
FT   VARIANT     144    144       S -> C (in dbSNP:rs766737607).
FT                                {ECO:0000269|PubMed:15175154,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041625.
FT   VARIANT     151    151       N -> Y (in dbSNP:rs750788715).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041626.
FT   VARIANT     160    160       D -> N. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041627.
FT   VARIANT     167    167       A -> V. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041628.
FT   VARIANT     320    320       D -> G. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041629.
FT   VARIANT     465    465       G -> S (in dbSNP:rs200419100).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041630.
FT   VARIANT     546    546       H -> R (in dbSNP:rs376234691).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041631.
FT   VARIANT     588    588       A -> S (in dbSNP:rs750840136).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041632.
FT   VARIANT     612    612       I -> K (in dbSNP:rs17842615).
FT                                {ECO:0000269|PubMed:15175154,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041633.
FT   VARIANT     753    753       S -> C (in dbSNP:rs569679854).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041634.
FT   VARIANT     809    809       S -> C. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041635.
FT   VARIANT     812    812       R -> C. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041636.
FT   VARIANT     829    829       V -> I. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041637.
FT   VARIANT     832    832       N -> D (in dbSNP:rs192246457).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041638.
FT   VARIANT     952    952       A -> G (in dbSNP:rs555078480).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041639.
FT   VARIANT     969    969       N -> S. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041640.
FT   VARIANT    1016   1016       F -> L. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041641.
FT   VARIANT    1029   1029       R -> Q. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041642.
FT   VARIANT    1072   1072       T -> S (in dbSNP:rs45516593).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041643.
FT   VARIANT    1103   1103       N -> H (in dbSNP:rs563883658).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041644.
FT   VARIANT    1275   1275       P -> R. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041645.
FT   VARIANT    1292   1292       Q -> P. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041646.
FT   VARIANT    1332   1332       I -> V. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041647.
FT   VARIANT    1358   1358       S -> P. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041648.
FT   VARIANT    1418   1418       R -> T (in dbSNP:rs17731779).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041649.
FT   VARIANT    2171   2171       S -> C (in a breast pleomorphic lobular
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041650.
FT   VARIANT    2258   2258       G -> S (in dbSNP:rs35572280).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041651.
FT   VARIANT    2345   2345       M -> K (in dbSNP:rs56276814).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041652.
FT   VARIANT    2730   2730       Q -> E (in dbSNP:rs34960798).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041653.
FT   VARIANT    2889   2889       G -> S (in dbSNP:rs35952340).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041654.
FT   VARIANT    2899   2899       P -> A (in dbSNP:rs55782217).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041655.
FT   VARIANT    3239   3239       I -> T (in a breast infiltrating ductal
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041656.
FT   VARIANT    3583   3583       K -> Q (in a breast infiltrating ductal
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041657.
FT   MUTAGEN    2335   2335       D->A: Loss of function.
FT                                {ECO:0000269|PubMed:11331269,
FT                                ECO:0000269|PubMed:11544179,
FT                                ECO:0000269|PubMed:15175154}.
FT   CONFLICT     14     14       G -> GGGGG (in Ref. 2; BAB70696).
FT                                {ECO:0000305}.
FT   CONFLICT     20     20       K -> N (in Ref. 2; BAB70696).
FT                                {ECO:0000305}.
FT   CONFLICT     22     22       P -> S (in Ref. 2; BAB70696).
FT                                {ECO:0000305}.
FT   CONFLICT     40     40       D -> G (in Ref. 2; BAB70696).
FT                                {ECO:0000305}.
FT   CONFLICT    686    686       S -> A (in Ref. 2; BAB70696).
FT                                {ECO:0000305}.
FT   CONFLICT    743    743       K -> R (in Ref. 2; BAB70696).
FT                                {ECO:0000305}.
FT   CONFLICT   1193   1193       C -> F (in Ref. 2; BAB70696).
FT                                {ECO:0000305}.
FT   CONFLICT   2009   2009       K -> R (in Ref. 2; BAB70696).
FT                                {ECO:0000305}.
FT   CONFLICT   2077   2077       S -> N (in Ref. 1; AAK58892).
FT                                {ECO:0000305}.
SQ   SEQUENCE   3661 AA;  410501 MW;  216A55F3121F5829 CRC64;
     MSRRAPGSRL SSGGGGGGTK YPRSWNDWQP RTDSASADPD NLKYSSSRDR GGSSSYGLQP
     SNSAVVSRQR HDDTRVHADI QNDEKGGYSV NGGSGENTYG RKSLGQELRV NNVTSPEFTS
     VQHGSRALAT KDMRKSQERS MSYSDESRLS NLLRRITRED DRDRRLATVK QLKEFIQQPE
     NKLVLVKQLD NILAAVHDVL NESSKLLQEL RQEGACCLGL LCASLSYEAE KIFKWIFSKF
     SSSAKDEVKL LYLCATYKAL ETVGEKKAFS SVMQLVMTSL QSILENVDTP ELLCKCVKCI
     LLVARCYPHI FSTNFRDTVD ILVGWHIDHT QKPSLTQQVS GWLQSLEPFW VADLAFSTTL
     LGQFLEDMEA YAEDLSHVAS GESVDEDVPP PSVSLPKLAA LLRVFSTVVR SIGERFSPIR
     GPPITEAYVT DVLYRVMRCV TAANQVFFSE AVLTAANECV GVLLGSLDPS MTIHCDMVIT
     YGLDQLENCQ TCGTDYIISV LNLLTLIVEQ INTKLPSSFV EKLFIPSSKL LFLRYHKEKE
     VVAVAHAVYQ AVLSLKNIPV LETAYKLILG EMTCALNNLL HSLQLPEACS EIKHEAFKNH
     VFNVDNAKFV VIFDLSALTT IGNAKNSLIG MWALSPTVFA LLSKNLMIVH SDLAVHFPAI
     QYAVLYTLYS HCTRHDHFIS SSLSSSSPSL FDGAVISTVT TATKKHFSII LNLLGILLKK
     DNLNQDTRKL LMTWALEAAV LMKKSETYAP LFSLPSFHKF CKGLLANTLV EDVNICLQAC
     SSLHALSSSL PDDLLQRCVD VCRVQLVHSG TRIRQAFGKL LKSIPLDVVL SNNNHTEIQE
     ISLALRSHMS KAPSNTFHPQ DFSDVISFIL YGNSHRTGKD NWLERLFYSC QRLDKRDQST
     IPRNLLKTDA VLWQWAIWEA AQFTVLSKLR TPLGRAQDTF QTIEGIIRSL AAHTLNPDQD
     VSQWTTADND EGHGNNQLRL VLLLQYLENL EKLMYNAYEG CANALTSPPK VIRTFFYTNR
     QTCQDWLTRI RLSIMRVGLL AGQPAVTVRH GFDLLTEMKT TSLSQGNELE VTIMMVVEAL
     CELHCPEAIQ GIAVWSSSIV GKNLLWINSV AQQAEGRFEK ASVEYQEHLC AMTGVDCCIS
     SFDKSVLTLA NAGRNSASPK HSLNGESRKT VLSKPTDSSP EVINYLGNKA CECYISIADW
     AAVQEWQNAI HDLKKSTSST SLNLKADFNY IKSLSSFESG KFVECTEQLE LLPGENINLL
     AGGSKEKIDM KKLLPNMLSP DPRELQKSIE VQLLRSSVCL ATALNPIEQD QKWQSITENV
     VKYLKQTSRI AIGPLRLSTL TVSQSLPVLS TLQLYCSSAL ENTVSNRLST EDCLIPLFSE
     ALRSCKQHDV RPWMQALRYT MYQNQLLEKI KEQTVPIRSH LMELGLTAAK FARKRGNVSL
     ATRLLAQCSE VQLGKTTTAQ DLVQHFKKLS TQGQVDEKWG PELDIEKTKL LYTAGQSTHA
     MEMLSSCAIS FCKSVKAEYA VAKSILTLAK WIQAEWKEIS GQLKQVYRAQ HQQNFTGLST
     LSKNILTLIE LPSVNTMEEE YPRIESESTV HIGVGEPDFI LGQLYHLSSV QAPEVAKSWA
     ALASWAYRWG RKVVDNASQG EGVRLLPREK SEVQNLLPDT ITEEEKERIY GILGQAVCRP
     AGIQDEDITL QITESEDNEE DDMVDVIWRQ LISSCPWLSE LDESATEGVI KVWRKVVDRI
     FSLYKLSCSA YFTFLKLNAG QIPLDEDDPR LHLSHRVEQS TDDMIVMATL RLLRLLVKHA
     GELRQYLEHG LETTPTAPWR GIIPQLFSRL NHPEVYVRQS ICNLLCRVAQ DSPHLILYPA
     IVGTISLSSE SQASGNKFST AIPTLLGNIQ GEELLVSECE GGSPPASQDS NKDEPKSGLN
     EDQAMMQDCY SKIVDKLSSA NPTMVLQVQM LVAELRRVTV LWDELWLGVL LQQHMYVLRR
     IQQLEDEVKR VQNNNTLRKE EKIAIMREKH TALMKPIVFA LEHVRSITAA PAETPHEKWF
     QDNYGDAIEN ALEKLKTPLN PAKPGSSWIP FKEIMLSLQQ RAQKRASYIL RLEEISPWLA
     AMTNTEIALP GEVSARDTVT IHSVGGTITI LPTKTKPKKL LFLGSDGKSY PYLFKGLEDL
     HLDERIMQFL SIVNTMFATI NRQETPRFHA RHYSVTPLGT RSGLIQWVDG ATPLFGLYKR
     WQQREAALQA QKAQDSYQTP QNPGIVPRPS ELYYSKIGPA LKTVGLSLDV SRRDWPLHVM
     KAVLEELMEA TPPNLLAKEL WSSCTTPDEW WRVTQSYARS TAVMSMVGYI IGLGDRHLDN
     VLIDMTTGEV VHIDYNVCFE KGKSLRVPEK VPFRMTQNIE TALGVTGVEG VFRLSCEQVL
     HIMRRGRETL LTLLEAFVYD PLVDWTAGGE AGFAGAVYGG GGQQAESKQS KREMEREITR
     SLFSSRVAEI KVNWFKNRDE MLVVLPKLDG SLDEYLSLQE QLTDVEKLQG KLLEEIEFLE
     GAEGVDHPSH TLQHRYSEHT QLQTQQRAVQ EAIQVKLNEF EQWITHYQAA FNNLEATQLA
     SLLQEISTQM DLGPPSYVPA TAFLQNAGQA HLISQCEQLE GEVGALLQQR RSVLRGCLEQ
     LHHYATVALQ YPKAIFQKHR IEQWKTWMEE LICNTTVERC QELYRKYEMQ YAPQPPPTVC
     QFITATEMTL QRYAADINSR LIRQVERLKQ EAVTVPVCED QLKEIERCIK VFLHENGEEG
     SLSLASVIIS ALCTLTRRNL MMEGAASSAG EQLVDLTSRD GAWFLEELCS MSGNVTCLVQ
     LLKQCHLVPQ DLDIPNPMEA SETVHLANGV YTSLQELNSN FRQIIFPEAL RCLMKGEYTL
     ESMLHELDGL IEQTTDGVPL QTLVESLQAY LRNAAMGLEE ETHAHYIDVA RLLHAQYGEL
     IQPRNGSVDE TPKMSAGQML LVAFDGMFAQ VETAFSLLVE KLNKMEIPIA WRKIDIIREA
     RSTQVNFFDD DNHRQVLEEI FFLKRLQTIK EFFRLCGTFS KTLSGSSSLE DQNTVNGPVQ
     IVNVKTLFRN SCFSEDQMAK PIKAFTADFV RQLLIGLPNQ ALGLTLCSFI SALGVDIIAQ
     VEAKDFGAES KVSVDDLCKK AVEHNIQIGK FSQLVMNRAT VLASSYDTAW KKHDLVRRLE
     TSISSCKTSL QRVQLHIAMF QWQHEDLLIN RPQAMSVTPP PRSAILTSMK KKLHTLSQIE
     TSIATVQEKL AALESSIEQR LKWAGGANPA LAPVLQDFEA TIAERRNLVL KESQRASQVT
     FLCSNIIHFE SLRTRTAEAL NLDAALFELI KRCQQMCSFA SQFNSSVSEL ELRLLQRVDT
     GLEHPIGSSE WLLSAHKQLT QDMSTQRAIQ TEKEQQIETV CETIQNLVDN IKTVLTGHNR
     QLGDVKHLLK AMAKDEEAAL ADGEDVPYEN SVRQFLGEYK SWQDNIQTVL FTLVQAMGQV
     RSQEHVEMLQ EITPTLKELK TQSQSIYNNL VSFASPLVTD ATNECSSPTS SATYQPSFAA
     AVRSNTGQKT QPDVMSQNAR KLIQKNLATS ADTPPSTVPG TGKSVACSPK KAVRDPKTGK
     AVQERNSYAV SVWKRVKAKL EGRDVDPNRR MSVAEQVDYV IKEATNLDNL AQLYEGWTAW
     V
//
